Imidazole derivatives

US7153874B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bernd Buettelmann · Palo Alto, US
• Simona M. Ceccarelli · Basel, CH
• Georg Jaeschke · Basel, CH
• Sabine Kolczewski · Lörrach, DE
• Richard Hugh Philip Porter · Sursee, CH
• Eric Vieira · Frenkendorf, CH

Key dates

• Filing date: Mar 8, 2004
• Grant date: Dec 26, 2006
• Expiry date: Sep 17, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides 4-[1-Aryl-imidazol-4-ylethynyl]-2-alkyl-pyridine and 1-heteroaryl-imidazol-4-ylethynyl]-2-alkyl-pyridine derivatives and pharmaceutically acceptable salts thereof for the treatment or prevention of disorders mediated in full or in part by metabotropic glutamate receptor 5. These disorders include, e.g. acute, traumatic and chronic degenerative processes of the nervous system, such as Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis and multiple sclerosis, psychiatric diseases, such as schizophrenia and anxiety, depression, pain and drug dependency.